Simon Baker CFA
Stock Analyst at Rothschild & Co Redburn
(1.20)
# 3,787
Out of 4,698 analysts
18
Total ratings
41.7%
Success rate
-2.6%
Average return
Main Sectors:
Stocks Rated by Simon Baker CFA
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRNA Moderna | Downgraded: Sell | $81 | $145.55 | -44.35% | 2 | Sep 3, 2026 | |
| NVO Novo Nordisk | Upgraded: Buy | n/a | $46.60 | - | 2 | Sep 16, 2025 | |
| GILD Gilead Sciences | Maintained: Buy | $143 | $151.00 | -5.29% | 1 | Sep 12, 2025 | |
| REGN Regeneron Pharmaceuticals | Initiated Coverage: Buy | $890 | $827.72 | n/a | 1 | Aug 14, 2025 | |
| AUTL Autolus Therapeutics | Upgraded: Buy | $13 | $2.24 | n/a | 1 | Nov 15, 2024 | |
| LON: 0QIU Novo Nordisk A/S | Maintained: Hold | kr 600.00 | kr 303.71 | n/a | 1 | Nov 8, 2024 | |
| EPA: IPN Ipsen S.A. | Maintained: Buy | €165.00 | €164.70 | n/a | 1 | Jun 15, 2024 | |
| SWX: NOVN Novartis AG | Downgraded: Sell | CHF 105.00 → CHF 80.00 | CHF 129.58 | n/a | 3 | Nov 27, 2023 | |
| BNTX BioNTech SE | Upgraded: Buy | $170 | $103.76 | n/a | 3 | May 17, 2023 | |
| ABT Abbott Laboratories | Initiated Coverage: Hold | n/a | $108.33 | n/a | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $43.47 | n/a | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $357.00 | n/a | 1 | Apr 1, 2020 |
Moderna
Sep 3, 2026
Downgraded: Sell
Price Target: $81
Current: $145.55
Upside: -44.35%
Novo Nordisk
Sep 16, 2025
Upgraded: Buy
Price Target: n/a
Current: $46.60
Upside: -
Gilead Sciences
Sep 12, 2025
Maintained: Buy
Price Target: $143
Current: $151.00
Upside: -5.29%
Regeneron Pharmaceuticals
Aug 14, 2025
Initiated Coverage: Buy
Price Target: $890
Current: $827.72
Upside: n/a
Autolus Therapeutics
Nov 15, 2024
Upgraded: Buy
Price Target: $13
Current: $2.24
Upside: n/a
Novo Nordisk A/S
Nov 8, 2024
Maintained: Hold
Price Target: kr 600.00
Current: kr 303.71
Upside: n/a
Ipsen S.A.
Jun 15, 2024
Maintained: Buy
Price Target: €165.00
Current: €164.70
Upside: n/a
Novartis AG
Nov 27, 2023
Downgraded: Sell
Price Target: CHF 105.00 → CHF 80.00
Current: CHF 129.58
Upside: n/a
BioNTech SE
May 17, 2023
Upgraded: Buy
Price Target: $170
Current: $103.76
Upside: n/a
Abbott Laboratories
Oct 14, 2021
Initiated Coverage: Hold
Price Target: n/a
Current: $108.33
Upside: n/a
Oct 14, 2021
Initiated Coverage: Buy
Price Target: n/a
Current: $43.47
Upside: n/a
Apr 1, 2020
Upgraded: Buy
Price Target: n/a
Current: $357.00
Upside: n/a